{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:46:48Z","timestamp":1755218808082,"version":"3.43.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.fjurol.2025.102905","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T02:50:58Z","timestamp":1747277458000},"page":"102905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["National Belgian survey on managing non-muscle invasive bladder cancer during Mitomycin and bacillus Calmette-Guerin shortage"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0171-7773","authenticated-orcid":false,"given":"Am\u00e9lie","family":"Bertrand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Roumeguere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Vandamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Fran\u00e7oise","family":"Spinoit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Herve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Assenmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0767-940X","authenticated-orcid":false,"given":"Karel","family":"Decaestecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2348-0599","authenticated-orcid":false,"given":"Alexandre","family":"Peltier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Di Gregorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Degraeve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2025.102905_bib0140","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102905_bib0145","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2025.102905_bib0150","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2025.102905_bib0155","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.eururo.2017.06.038","article-title":"Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients","volume":"73","author":"Bosschieter","year":"2018","journal-title":"Eur Urol"},{"issue":"12S","key":"10.1016\/j.fjurol.2025.102905_bib0160","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S1166-7087(20)30751-X","article-title":"French ccAFU guidelines - update 2020-2022: bladder cancer","volume":"30","author":"Roupr\u00eat","year":"2020","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2025.102905_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S202006","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) therapy for bladder cancer: an update","volume":"9","author":"Guallar-Garrido","year":"2020","journal-title":"Immunotargets Ther"},{"issue":"5","key":"10.1016\/j.fjurol.2025.102905_bib0170","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.purol.2021.12.008","article-title":"Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: feasability study from CC-AFU vessie","volume":"32","author":"Rollin","year":"2022","journal-title":"Prog Urol"},{"key":"10.1016\/j.fjurol.2025.102905_bib0175","doi-asserted-by":"crossref","first-page":"1293110","DOI":"10.3389\/fpubh.2023.1293110","article-title":"Prevention and management of health products shortages by the French national agency (ANSM), 10 years of experience","volume":"11","author":"Belgodere","year":"2023","journal-title":"Front Public Health"},{"issue":"10","key":"10.1016\/j.fjurol.2025.102905_bib0180","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.urolonc.2021.05.015","article-title":"Non-muscle invasive bladder cancer: an overview of potential new treatment options","volume":"39","author":"Shore","year":"2021","journal-title":"Urol Oncol"},{"issue":"68","key":"10.1016\/j.fjurol.2025.102905_bib0185","first-page":"1","article-title":"High-risk non-muscle invasive bladder cancer\u2014therapy options during intravesical BCG shortage","volume":"17","author":"Veeratterapillay","year":"2016","journal-title":"Curr Urol Rep"},{"issue":"5","key":"10.1016\/j.fjurol.2025.102905_bib0190","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2025.102905_bib0195","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102905_bib0200","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"issue":"15","key":"10.1016\/j.fjurol.2025.102905_bib0205","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.purol.2022.08.006","article-title":"French AFU Cancer Committee Guidelines - update 2022-2024: non-muscle-invasive bladder cancer (NMIBC)","volume":"32","author":"Neuzillet","year":"2022","journal-title":"Prog Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2025.102905_bib0210","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102905_bib0215","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.acuro.2022.06.001","article-title":"Reduced- vs full-dose BCG in bladder cancer: a systematic review and meta-analysis","volume":"47","author":"Verri","year":"2023","journal-title":"Acta s Urol Esp (Engl Ed)"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102905_bib0220","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.fjurol.2025.102905_bib0225","first-page":"851.e11","article-title":"Association of Bacillus Calmette\u2013Guerin shortages with bladder cancer recurrence: a single-center retrospective study","volume":"38","author":"Lee","year":"2020","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102905_bib0230","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.euf.2019.04.002","article-title":"Recurrence rate and cost consequence of the shortage of Bacillus Calmette-Gu\u00e9rin Connaught strain for bladder cancer patients","volume":"7","author":"Ourfali","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102905_bib0235","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.acuro.2022.12.003","article-title":"BCG shortage for intravesical instillation is associated with early tumoral recurrence in patients with high-risk non-muscle invasive bladder tumours","volume":"47","author":"P\u00e9rez-Aizpurua","year":"2023","journal-title":"Actas Urol Esp (Engl Ed)"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102905_bib0240","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bju.15661","article-title":"Reduced-dose bacillus Calmette-Gu\u00e9rin (BCG) in an era of BCG shortage: real-world experience from a tertiary cancer centre","volume":"130","author":"Lobo","year":"2022","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.fjurol.2025.102905_bib0245","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.purol.2020.12.012","article-title":"BCG strain shortage from 2012 to 2014: Evaluation of its impact on the management of patients with high-risk NMIBC","volume":"31","author":"Surlemont","year":"2021","journal-title":"Prog Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2025.102905_bib0250","doi-asserted-by":"crossref","first-page":"e651","DOI":"10.1016\/j.clgc.2020.03.013","article-title":"Quantifying the overall survival benefit with early radical cystectomy for patients with histologically confirmed T1 non-muscle-invasive bladder cancer","volume":"18","author":"Tully","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102905_bib0255","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.20.01665","article-title":"Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study","volume":"39","author":"Catto","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102905_bib0260","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/13696998.2023.2189860","article-title":"Evaluating the cost-utility of intravesical Bacillus Calmette-Gu\u00e9rin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK","volume":"26","author":"Grabe-Heyne","year":"2023","journal-title":"J Med Econ"},{"key":"10.1016\/j.fjurol.2025.102905_bib0265","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/CEOR.S341896","article-title":"Treatment outcomes of high-risk non-muscle invasive bladder cancer (HR-NMIBC) in real-world evidence (RWE) studies: systematic literature review (SLR)","volume":"14","author":"Musat","year":"2022","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.fjurol.2025.102905_bib0270","doi-asserted-by":"crossref","first-page":"1170124","DOI":"10.3389\/fonc.2023.1170124","article-title":"Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs","volume":"13","author":"Grabe-Heyne","year":"2023","journal-title":"Front Oncol"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295039302500052X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295039302500052X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T11:51:04Z","timestamp":1754481064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295039302500052X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":27,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S295039302500052X"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.102905","relation":{},"ISSN":["2950-3930"],"issn-type":[{"type":"print","value":"2950-3930"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National Belgian survey on managing non-muscle invasive bladder cancer during Mitomycin and bacillus Calmette-Guerin shortage","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.102905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102905"}}